Piper Sandler analyst Matt O’Brien lowered the firm’s price target on CVRx to $15 from $33 and keeps an Overweight rating on the shares after the company reported “soft” Q1 results and brought guidance down for the full year. While “disappointed in the disruption,” these situations sometimes arise when CEOs transition and material turnover in the sales force “does not change our view on the utility of Barostim and the market opportunity,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVRX:
- CVRx Awards Bonus for Key Role in Management Transition
- CVRx Reports First Quarter 2024 Financial and Operating Results
- CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
- CVRx announces availability of additional data supporting long-term benefits of Barostim
- CVRx announces additional data supporting long-term benefits of barostim